Johnson & Johnson on Tuesday reported quarterly results just above Wall Street expectations, helped by strong sales of its blockbuster psoriasis drug Stelara, which is expected to face fresh U.S. competition from biosimilar versions next year. Separately, the New Jersey-based drugmaker has tentatively agreed to pay about $700 million to settle an investigation brought by more than 40 states into the marketing of its talc products, according to the Wall Street Journal.
About the Author
